Baxter International Inc
$ 19.38
0.16%
05 Jun - close price
- Market Cap 10,009,169,000 USD
- Current Price $ 19.38
- High / Low $ 19.75 / 19.32
- Stock P/E N/A
- Book Value 11.70
- EPS -1.91
- Next Earning Report 2026-07-30
- Dividend Per Share $0.36
- Dividend Yield 1.86 %
- Next Dividend Date 2026-07-01
- ROA 0.03 %
- ROE -0.15 %
- 52 Week High 31.77
- 52 Week Low 15.72
About
Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.
Analyst Target Price
$21.54
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-20 | 2024-11-08 | 2024-08-06 | 2024-05-02 | 2024-02-08 | 2023-11-02 | 2023-07-27 |
| Reported EPS | 0.36 | 0.44 | 0.69 | 0.59 | 0.55 | 0.58 | 0.49 | 0.68 | 0.65 | 0.88 | 0.68 | 0.55 |
| Estimated EPS | 0.31 | 0.54 | 0.6 | 0.61 | 0.48 | 0.52 | 0.78 | 0.66 | 0.61 | 0.86 | 0.68 | 0.6 |
| Surprise | 0.05 | -0.1 | 0.09 | -0.02 | 0.07 | 0.06 | -0.29 | 0.02 | 0.04 | 0.02 | 0 | -0.05 |
| Surprise Percentage | 16.129% | -18.5185% | 15% | -3.2787% | 14.5833% | 11.5385% | -37.1795% | 3.0303% | 6.5574% | 2.3256% | 0% | -8.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.37 |
| Currency | USD |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-01 | 2026-04-01 | 2026-01-02 | 2025-10-01 | 2025-07-01 | 2025-04-01 | 2025-01-02 | 2024-10-01 | 2024-07-01 | 2024-04-01 |
| Amount | $0.01 | $0.01 | $0.01 | $0.17 | $0.17 | $0.17 | $0.17 | $0.29 | $0.29 | $0.29 |
Next Dividend Records
| Dividend per share (year): | $0.36 |
| Dividend Yield | 1.86% |
| Next Dividend Date | 2026-07-01 |
| Ex-Dividend Date | 2026-05-29 |
Recent News: BAX
2026-06-05 18:54:07
Solventum has released its executive compensation details for its first full year as a standalone company, including an $11.2 million severance package for former EVP and Medical Surgical Group President Chris Barry. While CEO Bryan Hanson's total compensation dropped significantly in 2025 to $20.1 million, the company also disclosed its median employee pay for the first time, noting a CEO-to-median-employee pay ratio of 245:1. This report details compensation for other top executives and highlights the company's financial performance in its MedSurg segment.
2026-06-05 14:13:09
FMR LLC has filed an amendment to its Schedule 13G/A, reporting a 10.3% beneficial ownership stake in Baxter International Inc. (NYSE: BAX), which amounts to 52,972,914.27 shares. The filing indicates that FMR LLC holds sole dispositive power over these shares. This disclosure provides insight into institutional holdings and changes in ownership for Baxter.
2026-06-04 18:10:10
Veru Inc. (VERU) is a biopharmaceutical company focused on developing oral therapies for cardiometabolic dysfunction and inflammation, with a pipeline centered on enobosarm for high-quality weight loss and sabizabulin for inflammatory risk in cardiovascular disease. The company's investment profile is highly dependent on the success of its late-stage clinical trials. This page provides financial data, key ratios, and recent news related to VERU.
2026-06-04 17:17:00
Baxter International Inc. (BAX) shares rose 4.37% on Thursday, closing at $19.35. Despite this daily gain, the stock underperformed compared to the broader market, with the S&P 500 and Dow Jones Industrial Average also seeing increases. The company's stock currently sits 39.61% below its 52-week high of $32.04.
2026-06-03 20:07:13
Baxter International executive James Teaff forfeited 321 shares of common stock on June 2, 2026, at $18.68 per share to cover tax withholding obligations arising from vested restricted stock units granted on June 2, 2025. This was a routine, non-discretionary transaction intended to satisfy taxes on equity compensation, and not an open-market sale. After the forfeiture, Teaff directly holds 31,063 shares of Baxter common stock, including those in the company's Employee Stock Plan.
2026-06-03 20:07:09
Baxter International Inc.'s interim CFO, Anita A. Zielinski, was granted 13,426 shares of common stock as a restricted stock unit (RSU) award. This grant, valued at $0.00 per share, is a one-time special award tied to her additional duties as interim CFO and will vest on the third anniversary of the grant date. Following this transaction, Zielinski directly holds 59,714 shares of Baxter common stock, including automatic reinvestment of dividends.
